Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Besifovir SCHEMBL2908200 | 1.00 | HDAC6 (0.44) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL3288053 | 0.84 | KDM4E (0.45) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL2909051 | 0.84 | KDM4E (0.42) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL6053847 | 0.84 | KDM4E (0.42) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL2912674 | 0.83 | CDK1 (0.47) | HSP90AA1HSP90AB1FGFR1SLC22A6POLB | |
| Lb80317 SCHEMBL2905773 | 0.83 | POLB (0.39) | FGFR1SLC22A6POLBHPRT1CYP3A4 | |
| SCHEMBL2912383 | 0.82 | HDAC6 (0.45) | HDAC6HSP90AA1HSP90AB1 | |
| SCHEMBL6053557 | 0.81 | KDM4E (0.40) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL6053562 | 0.81 | KDM4E (0.40) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL6257806 | 0.81 | POLB (0.38) | FGFR1SLC22A6POLBHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-12329741-B2 | HBV inhibitor and its use | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2025-06-17 | — | — | US | claimed |
| US-20250145680-A1 | NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF | REMD BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250134910-A1 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | SHAPERON INC. (KR) | 2025-05-01 | — | — | US | claimed |
| EP-4526338-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4526339-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4494709-A2 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2025-01-22 | — | — | EP | claimed |
| EP-4103567-B1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-10-23 | — | — | EP | claimed |
| US-20220211762-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | PAEAN BIOTECHNOLOGY INC. (KR) | 2022-07-07 | — | — | US | claimed |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | XI'AN XINTONG PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2022-06-16 | — | — | US | claimed |
| CN-114555608-A | Oxamide substituted tricyclic inhibitors of hepatitis b virus | 分子遗传国家研究所(INGM) | 2022-05-27 | — | — | CN | claimed |
| EP-3985010-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2022-04-20 | — | — | EP | claimed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | claimed |
| EP-3972979-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Antios Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3964219-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | Paean Biotechnology Inc. (KR) | 2022-03-09 | — | — | EP | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329741-B2 | HBV inhibitor and its use | HAVCR2, HDGF, ZC3HAV1 | HDAC6 2546/4885KDM4E 1947/4885ALDH1A1 3509/4885 |
| US-20250134910-A1 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | ACE, CYP46A1, NLRP3 | HDAC6 756/4885KDM4E 2776/4885ALDH1A1 2796/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | HDAC6 153/4885KDM4E 1347/4885ALDH1A1 1104/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | HDAC6 1110/4885KDM4E 3006/4885ALDH1A1 4721/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | HDAC6 3017/4885KDM4E 2709/4885ALDH1A1 4315/4885 |
| US-20220184035-A1 | HBV INHIBITOR AND ITS USE | HAVCR2, HDGF, ZC3HAV1 | HDAC6 2546/4885KDM4E 1947/4885ALDH1A1 3509/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | HDAC6 1220/4885KDM4E 4145/4885ALDH1A1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.